Aug 4, 2011 by Brian Orelli, PhDPfizer's Long-Shot Lipitor GambleDon't count on OTC Lipitor anytime soon.
Aug 3, 2011 by Brian Orelli, PhDArena Sheds a Few Pounds Off Its To-Do ListThe brian cancer issue seems to be rat specific.
Aug 1, 2011 by Brian Orelli, PhDBravo? Not Really.Teva's oral multiple sclerosis drug, laquinimod, fails to impress.
Jul 29, 2011 by Brian Orelli, PhDThe Big Bet on ADVENTRX PharmaceuticalsAn FDA decision on Exelbine approaches.
Jul 29, 2011 by Brian Orelli, PhDBristol-Myers Grows in the Wrong PlacesBristol-Myers has a solid quarter, but Plavix and currency movements aren't important.
Jul 29, 2011 by Brian Orelli, PhDThe Tale of 2 Generic-Drug MakersTeva and Mylan post strong quarters through wildly different means.
Jul 29, 2011 by Brian Orelli, PhDMerck's Making All the Right Long-Term MovesJob cuts, but they're not in research.
Jul 28, 2011 by Brian Orelli, PhDBut, But, But, I Thought You Were for Sale?BioSante raises cash -- guess it's not on the market.
Jul 28, 2011 by Brian Orelli, PhDIs Pfizer Barking Up the Wrong Tree?Should the pharma giant spin off or sell its animal-health business?
Jul 27, 2011 by Brian Orelli, PhDSwitching Partners Provides a Big Shot in the ArmMerck loves Cardiome more than Astellas does.
Jul 27, 2011 by Brian Orelli, PhDNot Hypergrowth, but Good EnoughGilead posts a double-digit revenue gain.
Jul 27, 2011 by Brian Orelli, PhDGood Combo; Too Bad There's CompetitionVertex’s VX-222 helps standard of care but still requires an injected medication.
Jul 26, 2011 by Brian Orelli, PhDLike It (Almost) Never HappenedNeoprobe gets a boost from management explanation.
Jul 26, 2011 by Brian Orelli, PhDAll Tysabri, All the TimeThe most important drug in Biogen's portfolio impresses.
Jul 25, 2011 by Brian Orelli, PhDExpress-Medco: Just What the Doctor PrescribedA good fit in a business where size matters.
